Efficacy News and Research

RSS

Inotek announces final data from trabodenoson Phase 2 trial on PAOG or ocular hypertension

Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that final data from a Phase 2 clinical trial of trabodenoson, also known as INO-8875, in patients with primary open-angle glaucoma or ocular hypertension will be presented at the Ophthalmology Innovation Summit on Thursday, November 8, 2012 at the Chicago Marriott Downtown Magnificent Mile in Chicago, IL.

2 Nov 2012

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

A drug which was originally developed to treat leukaemia and other cancers of the immune system offers substantial improvements over existing treatments in reducing relapse rates for people with multiple sclerosis (MS), even when they have not responded well to first-line treatment, according to the results of two phase 3 trials published Online First in The Lancet.

1 Nov 2012

Nitisinone treatment effectively prevents tyrosinemia in children

A consortium of Quebec researchers coordinated by the Medical Genetics Service of the Sainte-Justine UHC has just published the findings of a 25-year study on the treatment of tyrosinemia, a life-threatening liver disease of genetic origin, which is screened at birth in the province of Quebec, where it is much more frequent than anywhere else in the world.

1 Nov 2012

Controlling depression can improve health status and social functioning in patients with heart failure

Controlling depression in patients with heart failure can improve health status, social functioning and quality of life, according to a new study by psychiatrists and cardiologists at the UC Davis and Duke University schools of medicine.

1 Nov 2012

Novartis resumes distribution of two seasonal influenza vaccines in Canada

Novartis Pharmaceuticals Canada Inc. has announced it is resuming distribution of two seasonal influenza vaccines in Canada, Fluad and Agriflu, following the announcement by Health Canada earlier today that it has completed its review of safety information for Agriflu and Fluad and is releasing the two vaccines for immediate use.

1 Nov 2012

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, updated preliminary data from an ongoing randomized 110 patient Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

1 Nov 2012

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Isis Pharmaceuticals, Inc. announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston.

1 Nov 2012

AKP America commences ART-123 Phase 3 trial in severe sepsis patients with coagulopathy

Asahi Kasei Pharma America Corp. today announced the initiation of an 800-patient Phase 3 clinical trial for ART-123 (recombinant human thrombomodulin, marketed as Recomodulin in Japan) in severe sepsis patients with coagulopathy.

1 Nov 2012

‘Off the shelf’ stem cells show promise for perianal fistula

Expanded allogenic adipose-derived stem cells are effective for the treatment of perianal fistula in patients with Crohn’s disease, suggest the results of a phase I/II trial.

31 Oct 2012

SSRIs should be prescribed with great caution to those attempting to get pregnant

Elevated risk of miscarriage, preterm birth, neonatal health complications and possible longer term neurobehavioral abnormalities, including autism, suggest that a class of antidepressants known as selective serotonin reuptake inhibitors (SSRI) should only be prescribed with great caution and with full counseling for women experiencing depression and attempting to get pregnant, say researchers at Beth Israel Deaconess Medical Center, Tufts Medical Center and MetroWest Medical Center.

31 Oct 2012

SSRIs should be prescribed with great caution to those attempting to get pregnant

31 Oct 2012

Telephone-based tinnitus-management program shows promise

Results from a pilot study suggest that people with tinnitus benefit from a progressive management program including cognitive behavioral therapy.

30 Oct 2012

Top-line results from Neuraltus’ NP001 Phase 2 study on amyotrophic lateral sclerosis

Neuraltus Pharmaceuticals, a private biopharmaceutical company developing novel therapies for rare neurological disorders, announced today top-line results from the Company's Phase 2 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Oct 2012

CINJ visiting scientist receives International - U.S. Annual Meeting Scientific Abstract Award

Songbing Qin, MD, a visiting scientist to The Cancer Institute of New Jersey, has received the International - U.S. Annual Meeting Scientific Abstract Award at the 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO) being held in Boston this week.

30 Oct 2012

MiMedx third quarter revenue increases 270% to $8.0 million

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended September 30, 2012.

30 Oct 2012

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.

29 Oct 2012

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

29 Oct 2012

Range of biopharma solutions from Malvern Instruments extended by distribution agreement with Affinity Biosensors

Materials characterization company Malvern Panalytical. (Malvern Panalytical, UK) has signed an exclusive distribution agreement with Affinity Biosensors LLC (Santa Barbara, CA, USA) which will extend the range of solutions that Malvern Panalytical offers to the biopharmaceutical sector.

From Malvern Panalytical 29 Oct 2012

Triapine shows promise in treating breast cancer

Students at Tennessee Tech University are developing and testing a series of chemical compounds that show promise of stopping cancer in its tracks.

29 Oct 2012

FDA clears MAQUET’s new SENSATION PLUS 7.5Fr. 40cc intra-aortic balloon catheter

MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE mark approval for its new SENSATION PLUS 7.5Fr. 40cc intra-aortic balloon (IAB) catheter.

29 Oct 2012

Efficacy News and Research

Inotek announces final data from trabodenoson Phase 2 trial on PAOG or ocular hypertension

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

Nitisinone treatment effectively prevents tyrosinemia in children

Controlling depression can improve health status and social functioning in patients with heart failure

Novartis resumes distribution of two seasonal influenza vaccines in Canada

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

AKP America commences ART-123 Phase 3 trial in severe sepsis patients with coagulopathy

‘Off the shelf’ stem cells show promise for perianal fistula

SSRIs should be prescribed with great caution to those attempting to get pregnant

SSRIs should be prescribed with great caution to those attempting to get pregnant

Telephone-based tinnitus-management program shows promise

Top-line results from Neuraltus’ NP001 Phase 2 study on amyotrophic lateral sclerosis

CINJ visiting scientist receives International - U.S. Annual Meeting Scientific Abstract Award

MiMedx third quarter revenue increases 270% to $8.0 million

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

Range of biopharma solutions from Malvern Instruments extended by distribution agreement with Affinity Biosensors

Triapine shows promise in treating breast cancer

FDA clears MAQUET’s new SENSATION PLUS 7.5Fr. 40cc intra-aortic balloon catheter

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News